Cohance Lifesciences Hits New 52-Week Low at Rs. 615.1

Cohance Lifesciences has reached a significant milestone today, hitting a new 52-week low of Rs. 615.1. This decline marks a notable downturn for the small-cap pharmaceutical and biotechnology company, which has seen its stock price decrease by 27.08% over the past 12 days. Today's performance reflects an underperformance against its sector, with a drop of 1.41%. The stock's intraday low of Rs. 615.1 represents a 2.29% decrease from the previous close. In terms of moving averages, Cohance Lifesciences is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a sustained downward trend. Over the past year, the stock has experienced a significant decline of 51.26%, contrasting sharply with the Sensex's performance, which has risen by 8.66% during the same period. The company's operating profit growth has been modest, averaging just 4.15% annually over the last five years, contributing to concerns about its long-term growth prospects. Additionally, 100% of promoter shares are pledged, which may exert further pressure on the stock in a declining market.